不同剂量瑞舒伐他汀对冠心病合并高胆固醇血症患者血脂及血清hs-CRP的影响

目的：对比不同剂量瑞舒伐他汀对冠心病（CAD）合并高胆固醇血症（HC）患者血脂及血清高敏C反应蛋白（hs-CRP）的影响。方法选择我院于2010年7月至2012年7月期间收治的CAD合并HC患者63例。所有患者根据给予药物剂量不同分为观察组37例和对照组26例，观察组采用40 mg/d瑞舒伐他汀治疗，对照组采用10 mg/d瑞舒伐他汀治疗。分别测定两组患者在服用不同剂量瑞舒伐他汀前及1个月后hs-CRP水平、血脂各成分及一般生化指标，并进行对比分析。结果两组患者治疗前后空腹血糖（FPG）、高密度脂蛋白胆固醇（HDL-C）、甘油三脂（TG）等指标比较差异均无统计学意义（P〉0.05）。为期1个月的治疗完成后，两组患者的低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、hs-CRP等指标与治疗前比较均下降，差异有统计学意义（P〈0.05），但观察组的降低效果显著优于对照组（P〈0.05）。结论瑞舒伐他汀药物治疗冠心病合并高胆固醇血症患者，对降低血脂及hs-CRP水平具有十分良好的效果，并且加大药物剂量时效果更加突出。

Effect of different dose of rosuvastatin on C-Reactive protein and blood-fat in patients with coronary artery disease accompanied by hypercholesteremia.

Objective To study the impact of different dose of rosuvastatin on the high-sensitivity C-reactive protein （hs-CRP） and blood-fat of patients with coronary artery disease （CAD） accompanied by hypercholesteremia （HC）. Methods Sixty-three patients with coronary artery disease accompanied by hypercholesteremia from July 2010 to July 2012 were divided into observation group and control group by drug dosage. The observation group was treated with rosu-vastatin 40 mg/d, and the control group was treated with rosuvastatin 10 mg/d. The patients in two groups were measured hs-CRP, lipid components and general biochemical parameters before treatment and a month later. Results In each group, there were no significant differences in fasting plasma glucose （FPG）, HDL-C and TG before and after treatment （P〉0.05）. After rosuvastatin treatment for one month, TC, LDL-C, HS-CRP in two groups were all significantly lower than those before treatment （P〈0.05）. The effect of reduction in the observation group was more significant than that in the control group （P〈0.05）. Conclusion The rosuvastatin can effectively reduce the level of hs-CRP and blood-fat of pa-tients with CAD accompanied by HC. High-dose of rosuvastatin was more effective than conventional-dose.